IRR inhibitors, also known as ionizing radiation response inhibitors, are a class of chemical compounds designed to modulate cellular responses to ionizing radiation (IR). Ionizing radiation, such as X-rays and gamma rays, induces various DNA lesions and damages, triggering intricate cellular signaling pathways. IRR inhibitors specifically target key components within these signaling cascades, aiming to regulate the cellular response to radiation stress.
These inhibitors play a crucial role in understanding the molecular mechanisms underlying the cellular reactions to ionizing radiation, which is essential for advancing both basic scientific knowledge and potential applications in various fields. One prominent example of IRR inhibitors is those targeting the DNA damage response (DDR) pathway. The DDR pathway is an intricate network of signaling events that coordinates cell cycle checkpoints, DNA repair, and apoptosis in response to DNA damage induced by ionizing radiation. IRR inhibitors may interact with proteins involved in DDR, such as ATM (ataxia-telangiectasia mutated) and ATR (ataxia-telangiectasia and Rad3-related), to modulate their activities. By influencing these critical components, IRR inhibitors provide researchers with valuable tools to dissect the molecular intricacies of cellular responses to ionizing radiation. Understanding the underlying biology facilitated by IRR inhibitors contributes to a broader comprehension of DNA repair mechanisms and aids in the identification of potential targets for further investigation and research in the field of radiation biology.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is a receptor tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR), and could indirectly affect INSRR. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib is an antineoplastic agent used in breast cancer research | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib inhibits cellular signaling by targeting multiple receptor tyrosine kinases (RTKs). This could indirectly influence the function of the INSRR. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a kinase inhibitor that decreases tumor cell proliferation. It could indirectly impact the INSRR protein through its activity on various kinases. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a multi-targeted kinase inhibitor, known to inhibit more than 19 different kinases and could indirectly impact the function of the INSRR. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a 2-phenylaminopyrimidine derivative that functions as a specific inhibitor of a number of tyrosine kinase enzymes. It could have an indirect effect on INSRR activity. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $172.00 $964.00 | 2 | |
AP 24534 is a multi-targeted kinase inhibitor. Its targets include BCR-ABL, an abnormal tyrosine kinase that is expressed in most cases of chronic myelogenous leukemia. This could impact the INSRR indirectly. | ||||||
Afatinib-d4 | 850140-72-6 (unlabeled) | sc-481821 | 10 mg | $4665.00 | ||
BIBW2992 is an available, irreversible inhibitor of EGFR and HER2. It could indirectly impact INSRR. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
Nilotinib is a selective BCR-ABL tyrosine kinase inhibitor that is studied in the research of chronic myeloid leukemia (CML). It could indirectly affect INSRR. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR inhibitor, like erlotinib, which could indirectly affect the INSRR protein. | ||||||